ALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs

Deep News

Yesterday

ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion.

HSBC Global Research noted that health products are expected to continue being ALI HEALTH's fastest-growing category, benefiting from its robust platform ecosystem. Regarding pharmaceuticals, while the company's continued focus on first-party sales (1P) profitability may limit sales growth, the firm believes that as social insurance claims tighten and offline traffic shifts online, ALI HEALTH will benefit from strong demand for innovative drugs. Combined with strong advertising momentum, HSBC has raised its revenue growth forecast for ALI HEALTH's fiscal year 2026 from the previous 9% year-over-year to 15% year-over-year. Profit margins are expected to improve due to the revenue structure shifting toward non-pharmaceutical products and enhanced 1P profit margins, with the company's fiscal year 2026 net profit growth potentially exceeding revenue growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1126765801"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126765801\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126765801?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 12:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126765801","market":"sh","top_or_hot":-1,"title":"ALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs","media":"Deep News","content":"<p>ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion.</p>\n<p>HSBC Global Research noted that health products are expected to continue being ALI HEALTH's fastest-growing category, benefiting from its robust platform ecosystem. Regarding pharmaceuticals, while the company's continued focus on first-party sales (1P) profitability may limit sales growth, the firm believes that as social insurance claims tighten and offline traffic shifts online, ALI HEALTH will benefit from strong demand for innovative drugs. Combined with strong advertising momentum, HSBC has raised its revenue growth forecast for ALI HEALTH's fiscal year 2026 from the previous 9% year-over-year to 15% year-over-year. Profit margins are expected to improve due to the revenue structure shifting toward non-pharmaceutical products and enhanced 1P profit margins, with the company's fiscal year 2026 net profit growth potentially exceeding revenue growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-09-09 12:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion.</p>\n<p>HSBC Global Research noted that health products are expected to continue being ALI HEALTH's fastest-growing category, benefiting from its robust platform ecosystem. Regarding pharmaceuticals, while the company's continued focus on first-party sales (1P) profitability may limit sales growth, the firm believes that as social insurance claims tighten and offline traffic shifts online, ALI HEALTH will benefit from strong demand for innovative drugs. Combined with strong advertising momentum, HSBC has raised its revenue growth forecast for ALI HEALTH's fiscal year 2026 from the previous 9% year-over-year to 15% year-over-year. Profit margins are expected to improve due to the revenue structure shifting toward non-pharmaceutical products and enhanced 1P profit margins, with the company's fiscal year 2026 net profit growth potentially exceeding revenue growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1142","symbol_name":"互联网与直销零售","start_time":0,"source_url":"","article_id":"1126765801","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126765801","pubTimestamp":1757391650,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion. HSBC Global Research noted that health products are expected to continue being...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1142":"互联网与直销零售","BK1502":"双十一","BK1591":"就地过年概念","BK1615":"港股-互联网","BK1189":"医疗保健技术","BK1247":"药品零售","BK1584":"蚂蚁金服概念","BK1501":"阿里概念股","BK1571":"互联网医疗","BK1617":"AI医疗","00241":"阿里健康","BK1589":"北水核心资产","BK1515":"抗疫概念","BK1610":"ETF&股票定投概念"},"translate_title":"阿里健康早盘大涨超6%分析师预计公司将受益于创新药强劲需求","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00241":1},"content_text":"ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion.\nHSBC Global Research noted that health products are expected to continue being ALI HEALTH's fastest-growing category, benefiting from its robust platform ecosystem. Regarding pharmaceuticals, while the company's continued focus on first-party sales (1P) profitability may limit sales growth, the firm believes that as social insurance claims tighten and offline traffic shifts online, ALI HEALTH will benefit from strong demand for innovative drugs. Combined with strong advertising momentum, HSBC has raised its revenue growth forecast for ALI HEALTH's fiscal year 2026 from the previous 9% year-over-year to 15% year-over-year. Profit margins are expected to improve due to the revenue structure shifting toward non-pharmaceutical products and enhanced 1P profit margins, with the company's fiscal year 2026 net profit growth potentially exceeding revenue growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}